Drugmakers May Be Delaying Price Hikes to Avoid Spotlight
This article is for subscribers only.
With drugmakers under the microscope, price hikes on branded medicines are off to a slow start in 2019.
According to a Goldman Sachs analysis, prices were raised on about 27 percent of the top 500 branded drugs, down from 47 percent last year. The average list price increase was only 4 percent, half what it was in 2018. “The lower magnitude of brand price increases could present modest downside risk to wholesaler earnings,” health-care services analyst Robert Jones wrote in a note to clients.